Inhalation CDMO Market (2026-2036)

The growth of this market is mainly driven by the regulatory transition away from high global warming potential propellants, which requires the reformulation, requalification and refiling of essentially every pressurised metered dose inhaler on the market within a defined period; the scarcity of commercial-scale filling capability for low global warming potential propellants, which is held by a small number of contract manufacturers; the technical difficulty of inhaled and nasal drug-device combination products, which few pharmaceutical companies retain the capability to develop internally; and the expansion of nasal delivery into systemic and central nervous system applications. In addition, the growth of inhaled biologics and peptides, the complexity of demonstrating bioequivalence for generic inhaled products, and continued outsourcing of device development and drug-device integration are further shaping the growth of this market.

The Inhalation CDMO Market, also referred to as the inhalation contract development and manufacturing market or the inhaled and nasal drug-device CDMO market, comprises the contracted development, testing and manufacture of medicines delivered to the lung or the nasal cavity. The market includes pressurised metered dose inhalers, dry powder inhalers in capsule, blister and multi-dose reservoir formats, nebuliser solutions and suspensions including blow-fill-seal unit-dose presentations, nasal sprays and nasal powders, and soft mist and other novel inhalers. Services span formulation and product development, device development and drug-device integration, analytical and bioequivalence testing including aerodynamic particle size distribution and delivered dose uniformity, clinical trial supply, commercial manufacture and filling, and regulatory support. The market ecosystem extends from propellant, device component and excipient suppliers through contract development and manufacturing organizations and device specialists to originator pharmaceutical companies, generic and specialty manufacturers, emerging biotechnology developers and the regulators and environmental authorities whose requirements determine what may be manufactured and how.

This market is defined by technical difficulty rather than by scale. An inhaled product is a drug and a device operating as one system, in which the formulation, the metering valve or blister, the actuator geometry and the patient inspiratory profile together determine the dose that reaches the lung. Pharmaceutical companies have retained less of this capability than almost any other formulation discipline, which is why outsourcing penetration in inhalation is higher than in conventional oral solid dose and why the contract organizations holding the capability occupy unusually defensible positions.

The event that will shape this market across the forecast period is regulatory and is already in force. Regulation (EU) 2024/573 on fluorinated greenhouse gases brings metered dose inhalers into the hydrofluorocarbon quota system for the first time, with a guaranteed quota allocation based on historical inhaler market share across 2025 and 2026, gradual integration into the wider hydrofluorocarbon phase-down from 2027 to 2030, and alignment by 2030 with broader reduction targets of approximately 85% below baseline, while labelling obligations applied from 1 January 2025 and reference values are recalculated every three years. Bringing inhalers into a quota system that tightens progressively, rather than banning them outright, means every pressurised metered dose inhaler must move to a lower global warming potential propellant on a timetable the manufacturer does not control.

The scale of work that implies is frequently underestimated, and it falls on exactly the capabilities contract organizations supply. A propellant or formulation change to a pressurised metered dose inhaler requires pharmaceutical quality assessment, device compatibility evaluation, clinical bridging studies, stability data and comparative performance testing, together with regulatory variations ranging from Type IA and IB to Type II, device change submissions and labelling revisions, which places the reformulation burden on development and regulatory capability rather than on filling capacity alone. A propellant change alters solubility, suspension behaviour, vapour pressure, spray plume and device compatibility, so the reformulated product is a new pharmaceutical development rather than a substitution, and every marketing authorisation affected requires a variation supported by data.

Capability to manufacture at commercial scale with the new propellants is scarce, and that scarcity is the commercial heart of this market. The Holmes Chapel site became the first contract development and manufacturing organization to manufacture a pressurised metered dose inhaler at commercial scale using HFO-1234ze, a near-zero global warming potential propellant, which establishes that low-global-warming-potential filling at commercial scale is available from a contract manufacturer rather than only from originator plants. A contract organization holding qualified commercial-scale low global warming potential filling capacity can serve originators and generic manufacturers that have neither the capital nor the time to build it, and the window in which that advantage exists is defined by the regulatory timetable rather than by competitive dynamics.

Capacity is being added, with public support in some cases. Bespak Group was separated from the Recipharm Group on 2 April 2024 to form a standalone contract development and manufacturing organization for pulmonary and nasal drug-device combination products, with its headquarters and pressurised metered dose inhaler manufacturing at Holmes Chapel in the United Kingdom and early-stage development laboratories in North Carolina, and it has announced investment in commercial-scale and pilot-scale filling lines for HFA-152a. Kindeva Drug Delivery has received a United Kingdom government grant of USD 33 million and has expanded its Loughborough facilities at the Charnwood campus to support the commercialisation of low global warming potential propellants. Investment of this kind, directed specifically at low global warming potential filling lines and supported by government grant funding, indicates both the scale of expected demand and the recognition by authorities that inhaler supply is a public health matter rather than a commercial one.

A necessary corrective sits alongside this. The underlying respiratory market is not growing quickly, and the device and component suppliers serving it report modest volume growth. In the second quarter of 2026, AptarGroup, Inc. reported reported sales growth of 6% to USD 1.03 billion with core sales growth of 1%, and Pharma segment sales of USD 458.2 million, up 4% as reported and 1% on a core basis, with adjusted EBITDA margin of 33.6%, down 180 basis points on unfavourable product mix, and management reported high single-digit core growth in prescription dispensing excluding emergency medicine destocking, citing central nervous system, asthma and chronic obstructive pulmonary disease therapies and nasal decongestants among growth drivers. Core sales growth of 1% in a pharmaceutical dispensing business serving respiratory and nasal applications indicates that treated patient volumes and device demand are expanding slowly, so the growth in this market is transition work and complexity rather than underlying prescription volume.

The growth that is not transition-dependent sits principally in nasal delivery. AptarGroup reported in the first quarter of 2026 that the pipeline for systemic nasal drug delivery continued to build, with Pharma segment sales of USD 438.6 million and an adjusted EBITDA margin of 33.3% against 34.8% a year earlier. Nasal administration is being developed for systemic and central nervous system indications in which rapid absorption, avoidance of first-pass metabolism or direct access to the central nervous system is the objective, which is a different commercial proposition from decongestants and allergic rhinitis and commands development and manufacturing work of greater value per programme.

The market includes pulmonary and nasal contract manufacturers, device specialists and diversified contract organizations with inhalation capability, among them Bespak, Kindeva Drug Delivery, Recipharm, Catalent, Aptar Pharma, Nemera, H&T Presspart, Lonza, Thermo Fisher Scientific, Vectura, Merxin, Aurena Laboratories, Renaissance Lakewood, PCI Pharma Services, Cipla and Glenmark Pharmaceuticals. Participants compete on qualified filling capacity and propellant capability, device development and drug-device integration expertise, analytical and bioequivalence testing capability, regulatory experience with inhaled and nasal submissions, inspection history, speed from contract to clinical supply, and the ability to carry a product from feasibility through to commercial supply within one quality system.

At the same time, the market faces challenges, including the capital intensity and qualification time of filling capacity that must be committed against a regulatory rather than a commercial timetable, the difficulty and cost of demonstrating bioequivalence for generic inhaled products, device intellectual property that constrains formulation choices, propellant and component supply concentration, and the risk that the transition workload arrives as a concentrated wave and then recedes. As a result, organizations that combine qualified low-propellant filling capacity, device and formulation development depth, analytical and regulatory capability and a nasal and inhaled biologics position beyond the transition are expected to capture the largest share of growth over the forecast period.